Recommendations for the Prevention & Treatment of Glucocorticoid - induced Osteoporosis
Glucocorticoid-induced bone loss should be prevented, and if present, should be treated. Supplementation with calcium and vitamin D at a dosage of 800 IU/day, or an activated form of vitamin D (e.g., alfacalcidiol at 1 micrograms/day or calcitriol at 0.5 micrograms/day), should be offered to all patients receiving glucocorticoids, to restore normal calcium balance. Antiresorptive agents are effective in the treatment of glucocorticoid-induced bone loss. All of these agents either prevent bone loss or modestly increase lumbar spine bone mass and maintain hip bone mass. The therapies to prevent or treat glucocorticoid-induced bone loss should be continued as long as the patient is receiving glucocorticoids.
In order to proceed further, you need to have an account on IDG.
Create a new account now
Registered users, you can login below to access this page.
Browse more articles in Guidelines
- AHA statement recommends lower BP targets for CAD patients
- ACC/AHA guidelines for CABG
- AHA Guidelines for CVD Prevention in Women Focus on Lifetime Risk
- American Academy of Pediatrics guidelines for Autism
- CDC Issues Guidelines for Preconception Care of Women
More Articles »